Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

10.55 +0.56 (+5.61%)

Delayed Quote Updated: 2:37 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zevra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed. ↗

August 13, 2025

Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.

Via Investor's Business Daily

Wednesday's session: gap up and gap down stocks ↗

August 13, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 13, 2025

Via Benzinga

Zevra Revenue Jumps 486 Percent in Q2 ↗

August 12, 2025

Via The Motley Fool

Topics Intellectual Property

A Look at Zevra Therapeutics's Upcoming Earnings Report ↗

August 11, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock ↗

September 24, 2024

Via Benzinga

Zevra Therapeutics Mixed Q2 Results: Details ↗

August 13, 2024

Zevra Therapeutics reported its second-quarter financial results Tuesday. Here's a look at the details.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 12, 2025

Via Benzinga

How Zevra's Miplyffa Could Transform Investment Strategies ↗

July 02, 2025

HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating on rare disease strength.

Via Benzinga

This Block Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

July 02, 2025

Via Benzinga

Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views ↗

May 14, 2025

Via Benzinga

Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On? ↗

May 14, 2025

Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results.

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Zevra Therapeutics's Earnings Outlook ↗

May 12, 2025

Via Benzinga

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗

May 01, 2025

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a...

Via Stocktwits

Topics Stocks

Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

March 13, 2025

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Earnings Scheduled For March 11, 2025 ↗

March 11, 2025

Via Benzinga

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease ↗

September 20, 2024

The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic...

Via Benzinga

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 19, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

August 13, 2024

ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

PubMatic, Eventbrite, Five9 And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

August 09, 2024

Via Benzinga

Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

August 05, 2024

Via Benzinga

FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases ↗

August 05, 2024

FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 23, 2024

Via Benzinga

Insiders Buying Zevra Therapeutics And 1 Other Stock ↗

July 18, 2024

Via Benzinga

Insiders Buying Barnes & Noble Education And 2 Other Stocks ↗

July 17, 2024

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.